Changes in Visual Function and Correlations with Inner Retinal Structure in Acute and Chronic Leber's Hereditary Optic Neuropathy Patients After Treatment with Idebenone

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Jan 7

PMID 33406801

Citations 14

Authors

Berthold Pemp

Christoph Mitsch

Karl Kircher

Andreas Reitner

Affiliations

Soon will be listed here.

Abstract

Progressive impairment and degeneration of retinal ganglion cells (RGC) and nerve fibers in Leber's hereditary optic neuropathy (LHON) usually cause permanent visual loss. Idebenone is currently the only approved treatment. However, its therapeutic potential in different stages of LHON has not been definitely clarified. We aimed to investigate the changes in visual function and correlations with retinal structure in acute and in chronic LHON patients after treatment with idebenone. Twenty-three genetically confirmed LHON patients were followed during treatment using logMAR charts, automated perimetry and optical coherence tomography (OCT). Mean visual acuity improved significantly in acute patients treated within 1 year from onset (-0.52 ± 0.46 logMAR from nadir), in early chronic patients who started after 1-5 years (-0.39 ± 0.27 logMAR from baseline), and in late chronic patients with treatment initiation after >5 years (-0.33 ± 0.28 logMAR from baseline, < 0.001 all groups). In acute and in chronic patients, strong correlations between OCT and visual function parameters were present only after treatment. This and the sustained visual recovery after treatment may indicate a reactivated signal transduction in dysfunctional RGC that survive the acute phase. Our results support previous evidence that idebenone has therapeutic potential in promoting visual recovery in LHON.

Citing Articles

Ganglion Cell Complex Thickness and Visual Function in Chronic Leber Hereditary Optic Neuropathy.

Hedstrom J, Nilsson M, Engvall M, Williams P, Venkataraman A Invest Ophthalmol Vis Sci. 2024; 65(12):4.

PMID: 39365263 PMC: 11457923. DOI: 10.1167/iovs.65.12.4.

The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy.

Layrolle P, Orssaud C, Leleu M, Payoux P, Chavanas S Biomedicines. 2024; 12(3).

PMID: 38540197 PMC: 10968140. DOI: 10.3390/biomedicines12030584.

Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.

Yu-Wai-Man P, Carelli V, Newman N, Silva M, Linden A, Van Stavern G Cell Rep Med. 2024; 5(3):101437.

PMID: 38428428 PMC: 10982982. DOI: 10.1016/j.xcrm.2024.101437.

Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy.

Aleo S, Del Dotto V, Romagnoli M, Fiorini C, Capirossi G, Peron C Cell Rep Med. 2024; 5(2):101383.

PMID: 38272025 PMC: 10897523. DOI: 10.1016/j.xcrm.2023.101383.

Idebenone Treatment in Patients with OPA1-Dominant Optic Atrophy: A Prospective Phase 2 Trial.

Valentin K, Georgi T, Riedl R, Aminfar H, Singer C, Klopstock T Neuroophthalmology. 2023; 47(5-6):237-247.

PMID: 38130806 PMC: 10732653. DOI: 10.1080/01658107.2023.2251575.

References

Carelli V, Carbonelli M, de Coo I, Kawasaki A, Klopstock T, Lagreze W . International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy. J Neuroophthalmol. 2017; 37(4):371-381. DOI: 10.1097/WNO.0000000000000570. View

Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M . A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011; 134(Pt 9):2677-86. PMC: 3170530. DOI: 10.1093/brain/awr170. View

Pemp B, Kircher K, Reitner A . Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset. Graefes Arch Clin Exp Ophthalmol. 2019; 257(12):2751-2757. DOI: 10.1007/s00417-019-04444-6. View

Goudarzvand M, Javan M, Mirnajafi-Zadeh J, Mozafari S, Tiraihi T . Vitamins E and D3 attenuate demyelination and potentiate remyelination processes of hippocampal formation of rats following local injection of ethidium bromide. Cell Mol Neurobiol. 2009; 30(2):289-99. PMC: 11498802. DOI: 10.1007/s10571-009-9451-x. View

Yu-Wai-Man P, Soiferman D, Moore D, Burte F, Saada A . Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy. Mitochondrion. 2017; 36:36-42. PMC: 5644719. DOI: 10.1016/j.mito.2017.01.004. View

Parisi V, Barbano L, Di Renzo A, Coppola G, Ziccardi L . Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study. PLoS One. 2019; 14(7):e0220435. PMC: 6660126. DOI: 10.1371/journal.pone.0220435. View

Lam B, Feuer W, Schiffman J, Porciatti V, Vandenbroucke R, Rosa P . Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial. JAMA Ophthalmol. 2014; 132(4):428-36. PMC: 4266137. DOI: 10.1001/jamaophthalmol.2013.7971. View

Acosta C, Cortes C, MacPhee H, Namaka M . Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair. CNS Neurol Disord Drug Targets. 2013; 12(8):1242-56. DOI: 10.2174/18715273113129990087. View

Takuma K, Yoshida T, Lee E, Mori K, Kishi T, Baba A . CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. Eur J Pharmacol. 2000; 406(3):333-9. DOI: 10.1016/s0014-2999(00)00701-9. View

10.

Carelli V, La Morgia C, Valentino M, Rizzo G, Carbonelli M, De Negri A . Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011; 134(Pt 9):e188. DOI: 10.1093/brain/awr180. View

11.

Fry L, Fahy E, Chrysostomou V, Hui F, Tang J, van Wijngaarden P . The coma in glaucoma: Retinal ganglion cell dysfunction and recovery. Prog Retin Eye Res. 2018; 65:77-92. DOI: 10.1016/j.preteyeres.2018.04.001. View

12.

Mowry E, Loguidice M, Daniels A, Jacobs D, Markowitz C, Galetta S . Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009; 80(7):767-72. DOI: 10.1136/jnnp.2008.165449. View

13.

Haefeli R, Erb M, Gemperli A, Robay D, Courdier Fruh I, Anklin C . NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One. 2011; 6(3):e17963. PMC: 3069029. DOI: 10.1371/journal.pone.0017963. View

14.

Carelli V, Rugolo M, Sgarbi G, Ghelli A, Zanna C, Baracca A . Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration. Biochim Biophys Acta. 2004; 1658(1-2):172-9. DOI: 10.1016/j.bbabio.2004.05.009. View

15.

Takeuchi R, Murase K, Furukawa Y, Furukawa S, Hayashi K . Stimulation of nerve growth factor synthesis/secretion by 1,4-benzoquinone and its derivatives in cultured mouse astroglial cells. FEBS Lett. 1990; 261(1):63-6. DOI: 10.1016/0014-5793(90)80637-x. View

16.

Naeimi R, Baradaran S, Ashrafpour M, Moghadamnia A, Ghasemi-Kasman M . Querectin improves myelin repair of optic chiasm in lyolecithin-induced focal demyelination model. Biomed Pharmacother. 2018; 101:485-493. DOI: 10.1016/j.biopha.2018.02.125. View

17.

Riordan-Eva P, Sanders M, Govan G, Sweeney M, Da Costa J, Harding A . The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain. 1995; 118 ( Pt 2):319-37. DOI: 10.1093/brain/118.2.319. View

18.

Barboni P, Carbonelli M, Savini G, Ramos C, Carta A, Berezovsky A . Natural history of Leber's hereditary optic neuropathy: longitudinal analysis of the retinal nerve fiber layer by optical coherence tomography. Ophthalmology. 2009; 117(3):623-7. DOI: 10.1016/j.ophtha.2009.07.026. View

19.

Kirkman M, Korsten A, Leonhardt M, Dimitriadis K, De Coo I, Klopstock T . Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009; 50(7):3112-5. DOI: 10.1167/iovs.08-3166. View

20.

Mordente A, Martorana G, Minotti G, Giardina B . Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol. 1998; 11(1):54-63. DOI: 10.1021/tx970136j. View